Informações de Regeneron Pharmaceuticals Inc

Mais detalhes de Regeneron Pharmaceuticals Inc Empresa

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.



Código da empresaREGN

Nome da EmpresaRegeneron Pharmaceuticals Inc

Data de listagemApr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

Número de funcionários15106

Tipo de títulosOrdinary Share

Fim do ano fiscalApr 02

Endereço777 Old Saw Mill River Road

CidadeTARRYTOWN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal10591

Telefone17813705000

Sitehttps://www.regeneron.com/

Código da empresaREGN

Data de listagemApr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

Executivos da empresa Regeneron Pharmaceuticals Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

54.39K

+1.82%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

54.39K

+1.82%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

Outro

421.70M

11.47%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

Outro

421.70M

11.47%

Distribuição de ações

Atualizado em: sáb, 30 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.07%

BlackRock Institutional Trust Company, N.A.

5.49%

State Street Investment Management (US)

4.68%

Dodge & Cox

3.70%

Fidelity Management & Research Company LLC

3.16%

Outro

73.90%

Investidores

Proporção

The Vanguard Group, Inc.

9.07%

BlackRock Institutional Trust Company, N.A.

5.49%

State Street Investment Management (US)

4.68%

Dodge & Cox

3.70%

Fidelity Management & Research Company LLC

3.16%

Outro

73.90%

Tipos de investidores

Investidores

Proporção

Investment Advisor

48.18%

Investment Advisor/Hedge Fund

28.87%

Hedge Fund

5.39%

Research Firm

2.72%

Pension Fund

2.56%

Bank and Trust

2.16%

Individual Investor

2.02%

Sovereign Wealth Fund

1.23%

Insurance Company

0.08%

Outro

6.77%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

2594

94.25M

91.26%

-4.09M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

9.37M

9%

+14.55K

+0.16%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.67M

5.44%

-75.61K

-1.32%

Jun 30, 2025

State Street Investment Management (US)

4.83M

4.64%

+42.34K

+0.88%

Jun 30, 2025

Dodge & Cox

3.83M

3.67%

+1.50M

+64.64%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.26M

3.13%

-4.14M

-55.90%

Jun 30, 2025

Capital International Investors

3.17M

3.04%

-823.87K

-20.65%

Jun 30, 2025

JP Morgan Asset Management

2.82M

2.7%

-1.26M

-30.95%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.47M

2.37%

-4.53K

-0.18%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

2.17M

2.09%

-7.70K

-0.35%

Aug 31, 2025

Putnam Investment Management, L.L.C.

2.03M

1.95%

+116.30K

+6.08%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: há 6 horas

Nome

Proporção

iShares Biotechnology ETF

5.44%

Amplify Weight Loss Drug & Treatment ETF

4.78%

JPMorgan Healthcare Leaders ETF

2.31%

SPDR S&P Biotech ETF

2.09%

Putnam Focused Large Cap Value ETF

1.57%

Pacer US Cash Cows 100 ETF

1.16%

Health Care Select Sector SPDR Fund

1.14%

JPMorgan Equity Premium Income ETF

0.8%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

0.76%

Indexperts Quality Earnings Focused ETF

0.66%

Ver Mais

iShares Biotechnology ETF

Proporção5.44%

Amplify Weight Loss Drug & Treatment ETF

Proporção4.78%

JPMorgan Healthcare Leaders ETF

Proporção2.31%

SPDR S&P Biotech ETF

Proporção2.09%

Putnam Focused Large Cap Value ETF

Proporção1.57%

Pacer US Cash Cows 100 ETF

Proporção1.16%

Health Care Select Sector SPDR Fund

Proporção1.14%

JPMorgan Equity Premium Income ETF

Proporção0.8%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

Proporção0.76%

Indexperts Quality Earnings Focused ETF

Proporção0.66%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados